Phase 2 Trial

In Detail

A Phase 2 trial builds on the safety data from Phase 1 by evaluating whether the treatment actually works for its intended condition. These studies typically enroll between 100 and 300 patients who have the specific disease or condition the drug targets. Phase 2 trials are often divided into Phase 2a (focused on optimal dosing) and Phase 2b (focused on efficacy). Researchers compare the treatment against a placebo or existing standard therapy to measure its therapeutic effect. Phase 2 trials commonly use randomized, controlled designs and may be double-blinded, meaning neither the participants nor the researchers know who receives the treatment versus the placebo. These studies usually last from several months to two years and closely monitor both efficacy endpoints and side effects. The data generated helps researchers design the larger Phase 3 trials, including which dose to use, which patient population benefits most, and which endpoints to measure. Approximately 33% of Phase 2 drugs advance to Phase 3, making this the stage with the highest attrition rate. Phase 2 is sometimes called the "proof of concept" stage because it provides the first meaningful evidence that a treatment has therapeutic value in humans. The results also inform the risk-benefit analysis that regulators will eventually evaluate.